Insilico Medicine (3696.HK) fell 4.67% in Hong Kong trading to HK$34.32.
The AI drug discovery sector extended losses in Hong Kong, with AI-focused stocks broadly under pressure after the Hang Seng Tech Index dropped more than 5% the previous session.
Insilico recently entered an $888 million partnership with Servier, bringing its total signed deal value in 2026 to nearly $11 billion across six collaborations each exceeding $100 million.
